Ameridose Shuts Down Voluntarily to Allow Investigation

.

Founded by the brothers-in-law who also founded the New England Compounding Center (NECC), Ameridose came into existence to help the market meet the growing need of hospital pharmacies.

The goal of the Ameridose founders was to deliver quality and reliable products to the customers. Earlier the company shut down voluntarily on October 10 to allow investigation into its conditions and sterility practices.

Since then, company agreed to close down a lot number of times to help the federal and state government to complete its investigations thoroughly. As per the latest news, the firm has now agreed to remain closed till February 22.

In November, a federal report asserted some 15 problems at Ameridose. This included inadequate sterility testing and vermin where these products undergo packaging and storage. The Food and Drug Administration also alleged that insects and birds were seen at the place.

The company has replied to the report and has said that it shall cooperate with the authorities fully. The closing of Ameridose has been extended by six weeks as reported by the Boston Globe. It said that according to a statement the Department of Public Health, federal and state government will continue investigations into "unsanitary conditions and questionable sterility practices at the facility".

 


Latest News

Ebola Treatments May Take Time to Hit the  Market
Fourth Quarter Loss Posted by Walgreen
Steve Wynn, Casino Magnate Says Gambling Industry is not about Slot Machines
News Corp. to Buy Move Inc. for $950 million
Will PayPal soon Look for Mergers with Mobile Payment Services to fight Competit
Ford Shares Drop With Profit Concerns
Dominion LNG Export Project Gets Green Signal from FERC
Second Quarter Shows Fastest Growth of U.S Economy
Stronger Safeguarding Rules for Service Members Against Predatory Lenders
Yahoo Urged to Buy Rival AOL Inc.
Slowing Down of Inflation May Make it Difficult for BOJ to Achieve its Target
B.K. Modi’s CIO Plans to Start Pre-IPO Fund